论文部分内容阅读
为期16周的随机、平行、对照研究。40例2型糖尿病患者均为继发口服药物失效,随机分为诺和锐30组与优泌乐25组,入组前从未使用过胰岛素治疗,每组各20例,在固定的糖尿病饮食及健康教育基础上,采用每日2次早晚餐前皮下注射诺和锐30或优泌乐25。观察治疗16周后两组7个时点血糖水平、HbA1c、低血糖发生次数、胰岛素用量。结果2型糖尿病继发口服药物失效后,采用诺和锐30或优泌乐25每日2次早晚餐前皮下注射后血糖均明显下降,7个时点血糖、HbA1c、低血糖发生次数、胰岛素用量比较均无显著性差异(P>0.05)。结论2型糖尿病患者口服降糖药物继发失效后采用诺和锐30或优泌乐2 5在疗效、安全性、依从性等方面均无差异。
A 16-week randomized, controlled, parallel study. 40 cases of type 2 diabetes patients were secondary oral drug failure, were randomly divided into Novo group Ruogen 30 and 25, before the group had never been treated with insulin, each group of 20 patients in the fixed diabetic diet And health education, based on the use of daily 2 times daily before and after subcutaneous injection of Novo Rui 30 or Uehara 25. After 16 weeks of treatment, blood glucose level, HbA1c, frequency of hypoglycemia and insulin dosage of the two groups were observed. Results After oral medication failure of type 2 diabetes mellitus, the blood sugar of Novo Rehru 30 or Uehara 25 twice a day before and after subcutaneous injection were significantly decreased. The blood glucose, HbA1c, incidence of hypoglycemia, insulin There was no significant difference in dosage (P> 0.05). Conclusion There is no difference in efficacy, safety and compliance between Novo-Rui-30 and Gu-er-Le-25 after oral administration of antidiabetic drugs in patients with type 2 diabetes.